Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Occidental Petroleum Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Occidental Petroleum Corporation trades at $53.54 (market cap $52.61B). The key difference: Occidental Petroleum Corporation is the larger of the two by market cap, and Occidental Petroleum Corporation pays a 1.97% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | OXY | |
|---|---|---|
Market Cap | $39.89B | $52.61B |
Sector | Health | Energy |
52-Week High | $491.22 | $66.24 |
52-Week Low | $278.09 | $38.92 |
Enterprise Value | $38.15B | $73.69B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Occidental Petroleum (OXY) trades at $52.89, up 1.13% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company shows robust profitability with a 22.42% net income margin and 14.04% ROE, though revenue has declined from $36.6B in 2022 to $21.6B in 2025. Recent news highlights rising oil prices from Middle East tensions boosting realized prices, while debt reduction and CrownRock asset integration remain focal points.
Outlook is mixed: analyst consensus is bullish with a $65.86 price target (50% buy ratings), but high P/E of 71.47 suggests premium valuation. Key opportunities include oil price leverage and carbon capture initiatives; risks involve oil volatility, debt levels, and execution under new CEO Richard Jackson. Cash flow trends show variability, with 2026 projecting positive net cash flow of $1.2B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
